619TiP PIKALO-1: A phase I/II trial of LY4064809 (STX-478), a pan-mutant-selective PI3Kα inhibitor in PIK3CA-mutant (PIK3CAm) advanced breast cancer (ABC) and other solid tumors (Trial in Progress)
Antonio Giordano(University of Siena), D. Juric(Center for Cancer Research), Alberto J. Montero(University Hospitals Seidman Cancer Center), Vincent Chau(Eli Lilly (United States)), Robert Wesolowski(The Ohio State University Wexner Medical Center), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), J. O'Shaughnessy(Texas Oncology), Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Patricia LoRusso(Yale Cancer Center), Amita Patnaik(South Texas Accelerated Research Therapeutics), G. Curigliano(University of Milan), M.J. De Miguel(HM Hospitales), Gennaro Daniele(Università Cattolica del Sacro Cuore), J. Rodon(The University of Texas MD Anderson Cancer Center), Pamela N. Münster(University of California, San Francisco), Douglas W. Orr(Mary Crowley Cancer Research Center), Teresa Cenarro Guerrero(Delfos Hospital), A. Elias(University of Colorado Denver), Aixa Soyano(Moffitt Cancer Center)
Cited by 0
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27
|Science|1995|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k